Men 10376
Based on 1 publication(s) in Google Scholar
Men 10376 is a selective tachykinin NK-2 receptor antagonist, with a Ki of 4.4 μM for rat small intestine NK-2 receptor.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 135306-85-3
- 화학식: C57H68N12O10
- 분자량:1081.22
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Men 10376
More
Biological Activity
Ki: 4.4 μM (NK-2 receptor, rat small intestine)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | EC50 |
78.1 nM
Compound: MEN-10376
|
Displacement of [3H]SR48968 from human recombinant NK2 receptor expressed in CHO cells
Displacement of [3H]SR48968 from human recombinant NK2 receptor expressed in CHO cells
|
[PMID: 16562853] |
Men 10376 is a selective tachykinin NK-2 receptor, with a Ki of 4.4 μM, and shows low selectivity for NK-1 and NK-3 receptors (Ki, >10 μM)[1]. Men 10376 shows pA2s of 5.66 and 8.08 for NK-1 (guinea-pig ileum) and NK-2 receptors (endothelium-deprived rabbit pulmonary artery). Men 10376 shows no effect on NK-3 receptor (Ki, >10 μM)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 135306-85-3
-
분자량 1081.22
-
화학식 C57H68N12O10
-
Synonyms
Neurokinin-2 receptor antagonist
-
Sequence
Asp-Tyr-{d-Trp}-Val-{d-Trp}-{d-Trp}-Lys-NH2
-
Sequence Shortening
DY-{d-Trp}-V-{d-Trp}{d-Trp}-K-NH2
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
순도&문서
References
[1]. Quartara L, et al. N-terminal truncated analogs of men 10376 as tachykinin NK-2 receptor antagonists. Life Sci. 1992;51(25):1929-36. [Content Brief]
[2]. Maggi CA, et al. In vivo evidence for tachykininergic transmission using a new NK-2 receptor-selective antagonist, MEN 10,376. J Pharmacol Exp Ther. 1991 Jun;257(3):1172-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)